2023 World Conference on Lung Cancer (Posters)-EP06.06. Expression of miR-30a-5p in Expression of Mir-30A-5P in Extracellular Vesicle as a Prognostic Biomarker for Non Small Cell Lung Cancer Therapy

EP06.06. Expression of miR-30a-5p in Expression of Mir-30A-5P in Extracellular Vesicle as a Prognostic Biomarker for Non Small Cell Lung Cancer Therapy - PDF(Slides)

Back to course

Pdf Summary

The study aimed to investigate the potential use of miR-30a-5p expression as a prognostic biomarker for non-small cell lung cancer therapy. The study included 16 patients with confirmed NSCLC, and miR-30a-5p expression levels were measured before and after therapy. The majority of the patients were male, smokers, had adenocarcinoma histopathology, and were at stage IV of the disease. After therapy, miR-30a-5p expression levels decreased in patients with partial response and stable disease, and increased in patients with progressive disease. The median overall survival was 39.6 weeks, and the median progression-free survival was 38.5 weeks. However, there was no correlation between PFS and miR-30a-5p expression. The molecular mechanism of miR-30a-5p in the tumor microenvironment is still unclear, and previous studies have shown inconsistent regulation of miR-30a. In this study, miR-30a-5p was found to be a potential minimally invasive biomarker for monitoring lung cancer therapy outcomes. Overall, the study suggests that miR-30a-5p expression in extracellular vesicles may serve as a prognostic biomarker for non-small cell lung cancer therapy.

Asset Subtitle

Mariska Pangaribuan

Meta Tag

Speaker Mariska Pangaribuan

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

miR-30a-5p expression

prognostic biomarker

non-small cell lung cancer therapy

NSCLC

miR-30a-5p

expression levels

tumor microenvironment

extracellular vesicles

prognostic

minimally invasive biomarker